Enliven Therapeutics earnings were -$85.2M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest ELVN earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$23.2M, up 16.1% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, ELVN reported annual earnings of -$71.6M, with 90.1% growth.
Enliven Therapeutics Earnings Reports & History FAQ
What were Enliven Therapeutics's earnings last quarter?
On ELVN's earnings call on Invalid Date, Enliven Therapeutics (NASDAQ: ELVN) reported Q3 2024 earnings per share (EPS) of -$0.48, up 5.88% year over year. Total ELVN earnings for the quarter were -$23.16 million. In the same quarter last year, Enliven Therapeutics's earnings per share (EPS) was -$0.51.
Is Enliven Therapeutics profitable or losing money?
As of the last Enliven Therapeutics earnings report, Enliven Therapeutics is currently losing money. Enliven Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2024 was -$85.21 million, a 37.97% increase year over year.
What was ELVN's earnings growth in the past year?
As of Enliven Therapeutics's earnings date in Invalid Date, Enliven Therapeutics's earnings has grown year over year. ELVN earnings in the past year totalled -$85.21 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.